Adverse effects of venlafaxine therapy and risk factors for their occurrence

Abstract

Pharmacovigilance is an important aspect of depression treatment, considering that 40–90% of patients experience side effects of antidepressant use. This paper discusses the issues of optimising the use of venlafaxine, including its pharmacodynamic and pharmacokinetic properties, indications, adverse effects and risk factors for their occurrence, such as co-morbidities or genetic polymorphisms and interactions with other drugs.